CERo Therapeutics (NASDAQ:CERO) Sets New 12-Month Low – Time to Sell?

Shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) hit a new 52-week low on Wednesday . The stock traded as low as $3.35 and last traded at $3.35, with a volume of 174874 shares traded. The stock had previously closed at $5.23.

CERo Therapeutics Stock Performance

The business’s 50-day simple moving average is $0.12 and its two-hundred day simple moving average is $0.14.

Insider Buying and Selling at CERo Therapeutics

In related news, major shareholder Bioventures Opportunities G. Yk sold 32,500 shares of the company’s stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $10.00, for a total transaction of $325,000.00. Following the sale, the insider now directly owns 226,207 shares of the company’s stock, valued at $2,262,070. This represents a 12.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 96,800 shares of company stock valued at $854,409 over the last quarter. 18.00% of the stock is owned by company insiders.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.